Pregled bibliografske jedinice broj: 1085701
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) // The American heart journal, 155 (2008), 1; 26-32 doi:10.1016/j.ahj.2007.09.009 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1085701 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Rationale, design, and baseline characteristics
for a large international trial of cardiovascular
disease prevention in people with dysglycemia: the
ORIGIN Trial (Outcome Reduction with an Initial
Glargine Intervention)
Autori
Gerstein Hertzel ; Yusuf Salim ; Riddle Matthew C ; Ryden Lars ; Bosch Jackie
Kolaboracija
ORIGIN Trial Investigators
Izvornik
The American heart journal (0002-8703) 155
(2008), 1;
26-32
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
MACE diabetes glargin
Sažetak
Ims: Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insufficient insulin secretion and are risk factors for cardiovascular (CV) events. Thus, targeting normal fasting glucose levels with insulin may reduce CV events. Previous studies suggest that omega-3 fatty acid supplements may reduce CV death ; however, their effect in high- risk dysglycemic individuals is not known. Methods: People aged > or = 50 years with evidence of CV disease and with IFG, IGT, newly detected or established diabetes (on 0 or 1 oral agent), and a local glycated hemoglobin < 150% of the upper limit of normal for that assay were recruited and allocated to (a) either 1 daily injection of insulin glargine with the dose titrated to achieve a fasting plasma glucose < or = 5.3 mmol/L (95 mg/dL), or standard glycemic care ; and (b) either omega-3-acid ethyl esters 90 (1 g consisting of EPA 465 mg and DHA 375 mg) or identical placebo, according to a 2 x 2 factorial design. The 2 different primary outcomes for the insulin and omega-3 fatty acid arms are CV events and CV death, respectively. Results: A total of 12, 612 (mean age 64, 35% women) people in 40 countries were randomized during a 2-year period ending December 2005. Eighty-two percent had established diabetes, 6% had new diabetes, and 12% had IGT or IFG ; the mean fasting plasma glucose was 7.3 mmol/L (131 mg/dL). Conclusions: The ORIGIN trial will determine whether or not either or both of these interventions can reduce CV events.
Izvorni jezik
Engleski
Znanstvena područja
Brodogradnja, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE